Hedyotis diffusa Willd Inhibits Colorectal Cancer Growth in Vivo via Inhibition of STAT3 Signaling Pathway by Cai, Qiaoyan et al.
Int. J. Mol. Sci. 2012, 13, 6117-6128; doi:10.3390/ijms13056117 
 





Hedyotis diffusa Willd Inhibits Colorectal Cancer Growth in Vivo 
via Inhibition of STAT3 Signaling Pathway 
Qiaoyan Cai 
1,2, Jiumao Lin 
1,2, Lihui Wei 
1,2, Ling Zhang 
1,2, Lili Wang 
1,2, Youzhi Zhan 
1,2, 
Jianwei Zeng 
1,2, Wei Xu 
3, Aling Shen 
1,2, Zhenfeng Hong 
1,2 and Jun Peng 
1,2,* 
1  Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional 
Chinese Medicine, 1 Huatuo Road, Minhou Shangjie, Fuzhou 350108, China;   
E-Mails: caiqiaoyan@fjtcm.edu.cn (Q.C.); linjiumao@gmail.com (J.L.); 282117657@qq.com (L.W.); 
391118966@qq.com (L.Z.); 987131517@qq.com (L.W.); 691306289@qq.com (Y.Z.); 
zjwtcm@qq.com (J.Z.); 277708930@qq.com (A.S.); zfhong1953@163.com (Z.H.) 
2  Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional 
Chinese Medicine, 1 Huatuo Road, Minhou Shangjie, Fuzhou 350108, China 
3  Department of Pharmacology, Fujian University of Traditional Chinese Medicine, 1 Huatuo Road, 
Minhou Shangjie, Fuzhou 350108, China; E-Mail: xwfjtcm@sina.com 
*  Author to whom correspondence should be addressed; E-Mail: pjunlab@hotmail.com;   
Tel.: +86-591-22861165; Fax: +86-591-22861157. 
Received: 28 March 2012; in revised form: 3 May 2012 / Accepted: 10 May 2012 /   
Published: 18 May 2012 
 
Abstract:  Signal  Transducer  and  Activator  of  Transcription  3  (STAT3),  a  common 
oncogenic mediator, is constitutively activated in many types of human cancers; therefore 
it is a major focus in the development of novel anti-cancer agents. Hedyotis diffusa Willd 
has been used as a major component in several Chinese medicine formulas for the clinical 
treatment of colorectal cancer (CRC). However, the precise mechanism of its anti-tumor 
activity remains largely unclear. Using a CRC mouse xenograft model, in the present study 
we evaluated the  effect of  the ethanol extract  of Hedyotis  diffusa Willd (EEHDW) on 
tumor growth in vivo and investigated the underlying molecular mechanisms. We found 
that EEHDW reduced tumor volume and tumor weight, but had no effect on body weight 
gain in CRC mice, demonstrating that EEHDW can inhibit CRC growth in vivo without 
apparent adverse effect. In addition, EEHDW treatment suppressed STAT3 phosphorylation 
in  tumor tissues, which in  turn  resulted in  the  promotion  of cancer cell apoptosis  and 
inhibition of proliferation. Moreover, EEHDW treatment altered the expression pattern of 
several important target genes of the STAT3 signaling pathway, i.e., decreased expression 
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of Cyclin D1, CDK4 and Bcl-2 as well as up-regulated p21 and Bax. These results suggest 
that  suppression  of  the  STAT3  pathway  might  be  one  of  the  mechanisms  by  which 
EEHDW treats colorectal cancer. 
Keywords: Hedyotis diffusa Willd; Chinese medicine; colorectal cancer; STAT3 pathway; 
apoptosis; proliferation 
 
Abbreviations: CRC, colorectal cancer; STAT3, signal transducer and activator of transcription 3; 
EEHDW, ethanol  extract of  Hedyotis  diffusa Willd;  DMSO, dimethyl sulfoxide; TCM, traditional 
Chinese medicine; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; 
PCNA, proliferating cell nuclear antigen. 
1. Introduction 
Colorectal cancer (CRC) is a major health problem in Western societies representing the second 
most common cause of cancer-related death. Both the yearly incidence and the mortality rate also 
increase steeply with age [1]. Although approximately 70–80% of patients are eligible for curative 
surgical  resection  at  the  time  of  diagnosis,  about  50%  of  all  newly  diagnosed  patients  ultimately 
develop  metastatic  disease  [2].  In  the  last  decade,  irinotecan,  oxaliplatin  and  the  standard 
fluorouracil-based chemotherapy regimens have set the new benchmark of survival for patients with 
metastatic CRC [3]. However, such treatments are also often coupled with serious toxicity and side 
effects such as anemia, leucopenia, thrombocytopenia and peripheral neuropathy [4]. Therefore, it is 
essential to find a safer and more effective way to treat CRC. The traditional Chinese medicine (TCM) 
has held and played an important role in primary health care in China and has been recently recognized 
by  Western countries  as an abundant  source  of novel  lead molecules  for modern drug discovery. 
Clinical  practice  has  also  shown  that  many  traditional  Chinese  herbal  medicines  have  antitumor 
activity, which sheds light on new therapeutic strategies for cancer treatment [4,5].   
Signal  transducer  and  activator  of  transcription  3  (STAT3)  plays  an  important  role  in  cell 
proliferation and apoptosis [6]. The activation of STAT3 is mediated by phosphorylation of tyrosine 
residue  705  in  the  Src  homology-2  domain  (SH2)  induced  by  a  wide  range  of  cytokine 
receptor-associated  kinases,  growth  factor  receptor  tyrosine  kinases,  and  non-receptor  tyrosine   
kinases  [7–9].  In  the  cytoplasm,  phosphorylated  STAT3  proteins  dimerize  and  translocate  to  the 
nucleus where they regulate the expression of various critical genes involved in cell proliferation and 
survival  [10,11].  Constitutive  activation  of  STAT3,  resulting  in  an  unregulated  increase  in  cell 
proliferation and reduction in cell apoptosis, is strongly correlated with the development of numerous 
types  of  cancer  including  CRC  [12–15].  Therefore,  inhibiting  cell  proliferation  and/or  promoting 
apoptosis  by  suppression  of  STAT3  activation  has  been  a  major  focus  in  the  development  of 
anti-cancer drugs.   
Hedyotis diffusa Willd (HDW), belonging to the Rubiaceae family, is a medicinal herb widely 
distributed in northeast Asia. As a well-known traditional Chinese herbal medicine, HDW has long 
been widely applied in the treatment of inflammation-related diseases, such as appendicitis, urethritis Int. J. Mol. Sci. 2012, 13  6119 
 
and  bronchitis  [16,17].  Modern  pharmacological  studies  proposed  that  HDW  displays  therapeutic 
effects  in  the  treatment  of  liver,  lung,  colon,  brain  and  pancreatic  cancers  [18–20].  Our  previous 
studies demonstrated that HDW can promote the apoptosis of human colon carcinoma cells and inhibit 
tumor angiogenesis in vitro [21,22]. However, the precise mechanism of its anti-cancer activity in vivo 
remains largely unknown. In order to further elucidate the anti-cancer mechanism of HDW, in the 
present study we evaluated the efficacy of HDW against tumor growth in vivo in the CRC mouse 
xenograft model and investigated the underlying molecular mechanisms. 
2. Materials and Methods   
2.1. Materials and Reagents   
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin, 
trypsin-EDTA,  Trizol  reagent  were  purchased  from  Invitrogen  (Carlsbad,  NM,  USA).  SuperScript  II 
reverse  transcriptase  was  provided  by  Promega  (Madison,  WI,  USA).  PCNA,  Bcl-2,  Bax,  P21, 
cyclinD1,  CDK4  antibodies,  horseradish  peroxidase  (HRP)-conjugated  secondary  anti-bodies  were 
obtained from Cell Signaling (Beverly, MA, USA). PCNA assay, TUNEL assay kit was purchased from 
R&D Systems (Minneapolis, MN, USA), VECTASTAIN Elite ABC kit was provided by VECTOR 
Laboratories (Burlingame, CA, USA). All the other chemicals used, unless otherwise stated, were 
obtained from Sigma Chemicals (St. Louis, MO, USA). 
2.2. Preparation of Ethanol Extract from Hedyotis diffusa Willd   
Authentic plant material was purchased from Guo Yi Tang Chinese Herbal medicine store, Fujian, 
China. The original herb was identified as Hedyotis diffusa Willd (HDW) by Dr. Wei Xu at Department 
of Pharmacology, Fujian University of Traditional Chinese Medicine, China. Ethanol extract of HDW 
(named EEHDW) was prepared as previously described [21]. Briefly, 500 g of HDW was extracted 
with 5000 mL of 85% ethanol using a refluxing method and filtered. The ethanol solvent was then 
evaporated on a rotary evaporator (Yarong, Model RE-2000, Shanghai, China). The resultant solution 
was concentrated to a relative density of 1.05, and the dried powder of EEHDW was obtained by a 
spraying  desiccation  method  using  a  spray  dryer  (Buchi,  Model  B-290,  Flawil,  Switzerland).  The 
working concentrations of EEHDW were made by dissolving the extract in saline to a concentration of   
0.6 g/mL.   
2.3. HPLC Analysis   
Chromatographic fingerprint was employed as quality control for different batches [23]. Samples 
were analyzed on an Agilent 1200 HPLC system (Agilent, Santa Clara, CA, USA) using a Sepax 
Sapphire-C18 column (250 mm ×  4.60 mm, 5 μm). The absorbance was measured at 355 nm. The 
mobile phase consisted of solvent A (methanol) and solvent B (water) at a flow rate of 1 mL/min with 
an injection volume of 10 μL. The gradient procedure was used as follows: 20–30% A at 0–15 min and 
40–60% A at 15–40 min. Based on the fingerprint as shown in Figure 1, we established an optimum 
and easily controlled procedure for preparing the EEHDW extract as mentioned above. If the peak Int. J. Mol. Sci. 2012, 13  6120 
 
areas of 1, 2, and 3 are in an optimum ratio of 1:6.4:9.3, all results from the study would readily   
be reproducible. 
Figure 1. Chromatographic profile of ethanol extract of Hedyotis diffusa Willd (EEHDW). 
In order to control the quality of  EEHDW, the peak areas of 1, 2, 3 should be in the 
optimum ratio of 1:6.4:9.2. An Agilent 1200 series HPLC system with DAD detector and a 
Sepax Sapphire-C18 column was used. The mobile phase consisted of solvent A (methanol) 
and solvent B (water). The gradient procedure was used as follows: 20–30% A at 0–15 min 
and 40–60% A at 15–40 min. The flow rate was 1.0 mL/min and the column temperature 
was set at 30 ° C. 
 
2.4. Cell Culture   
Human colon carcinoma HT-29 cells were obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA). Cells were grown in DMEM containing 10% (v/v) FBS, 100 units/mL penicillin 
and 100 μg/mL streptomycin in a 37 ° C humidified incubator with 5% CO2.   
2.5. Animals   
Athymic BALB/c nu/nu male mice (with an initial body weight of 20–22 g) were obtained from 
Shanghai  SLAC  Laboratory  Animal  Co.,  Ltd.  (Shanghai,  China)  and  housed  under  pathogen-free 
conditions  with  a  12  h  light/dark  cycle.  Food  and  water  were  given  ad  libitum  throughout  the 
experiment. All animal treatments were strictly in accordance with international ethical guidelines and 
the National Institutes of Health Guide concerning the Care and Use of Laboratory Animals, and the 
experiments were approved by the Institutional Animal Care and Use Committee of Fujian University 
of Traditional Chinese Medicine. 
2.6. In Vivo Nude Mouse Xenograft Study   
HT-29 cells were grown in culture and then detached by trypsinization, washed, and resuspended   
in serum-free DMEM. 1.5 ×  10
6 of cells mixed with Matrigel (1:1) were subcutaneously injected   
in  the right  flank area  of athymic nude mice to initiate tumor growth. After 3 days of xenograft 
implantation, mice were randomized into two groups (n = 12) and given intra-gastric administration of 
6 g/kg of EEHDW or saline daily, 5 days a week for 16 days. Body weight and tumor growth were Int. J. Mol. Sci. 2012, 13  6121 
 
measured every two days. Tumor growth was determined by measuring the major (L) and minor (W) 
diameter  with  a  caliper.  The  tumor  volume  was  calculated  according  to  the  following  formula:   
tumor  volume  =  π/6  ×   L  ×   W
2.  At  the  end  of  experiment,  the  animals  were  anaesthetized  with 
pelltobarbitalum natricum, and the tumor tissue was removed and weighed. 
2.7. Immunohistochemical Staining for PCNA 
Tumor  samples  were  fixed  in  10%  buffered  formalin  for  12  h,  and  subsequently  processed 
conventionally  for  paraffin-embedded  tumor  sections  (4  μm  thick).  The  tumor  sections  were  then 
deparafﬁnized and rehydrated via treatment with a series of xylenes and graded alcohols. Endogenous 
peroxidase activity of the sections was quenched by incubating in water containing 0.3% H2O2 for   
30  min.  Immunohistochemical  staining  was  performed  using  the  VECTASTAIN  elite  ABC  kit 
according to the manufacturer’s instructions. Briefly, after blocking non-speciﬁc proteins with normal 
serum in PBS (0.1% Tween 20), the sections were treated with PCNA antibody (at a dilution of 1:200) 
for 1 h. The sections were incubated with a biotinylated anti-rabbit IgG antibody for 30 min and then 
treated with the ABC reagent for 30 min. They were ﬁnally treated with DAB for 10 min. After the 
sections were washed and air-dried, cover slips were applied to the sections using permount slide 
mounting medium. PCNA was quantified by counting respective
 positive cells and total number of 
cells in five high-power fields (× 400) randomly selected in each slide, and the average proportion of 
positive cells in each  field were counted using the true color multi-functional cell image analysis 
management system (Image-Pro Plus, Media Cybernetics, Bethesda, MD, USA). 
2.8. In Situ Apoptosis Detection by TUNEL Staining   
The 4-µm -thick sections of tumor samples were analyzed by TUNEL staining using TumorTACS   
in  situ  Apoptosis  kit  (R&D  Systems,  Minneapolis,  MN,  USA).  Apoptotic  cells  were  counted  as 
DAB-positive cells (brown stained) at five arbitrarily selected microscopic fields at a magnification of 
400× . TUNEL-positive cells were counted as a percentage of the total cells. 
2.9. RNA Extraction and RT-PCR Analysis   
Total RNA was isolated from fresh tumor with Trizol reagent. Oligo(dT)-primed RNA (1 μg) was 
reverse  transcribed  with  SuperScript  II  reverse  transcriptase  according  to  the  manufacturer’s 
instructions.  The  obtained  cDNA  was  used  to  determine  the  mRNA  amount  of  Bcl-2,  Bax,  p21,   
Cyclin  D1  and  CDK4  by  PCR  with  Taq  DNA  polymerase  (Fermentas).  GAPDH  was  used  as  an 
internal  control.  The  primers  used  for  amplification  of  Bcl-2,  Bax,  p21,  Cyclin  D1,  CDK4  and 
GAPDH transcripts  are  as  follows:  Bcl-2 forward 5'-CAG CTG CAC  CTG ACG CCC TT-3 and 
reverse 5'-GCC TCC GTT ATC CTG GAT CC-3'; Bax forward 5'-TGC TTC AGG GTT TCA TCC 
AGG-3' and reverse 5'-TGG CAA AGT AGA AAA GGG CGA-3'; p21 forward 5'-GCG ACT GTG 
ATG CGC TAA TGG-3' and reverse 5'-TAG AAA TCT GTC ATG CTG GTC TGC-3'; Cyclin D1 
forward 5'-TGG ATG CTG GAG GTC TGC GAG GAA-3' and reverse 5'-GGC TTC GAT CTG CTC 
CTG GCA GGC-3'; CDK4 forward 5'-CAT GTA GAC CAG GAC CTA AGC-3' and reverse 5'-AAC Int. J. Mol. Sci. 2012, 13  6122 
 
TGG CGC ATC AGA TCC TAG-3'; GAPDH forward 5'-GT CAT CCA TGA CAA CTT TGG-3' and 
reverse 5'-GA GCT TGA CAA AGT GGT CGT-3'. 
2.10. Preparation of Tumor Homogenate and Western Immunoblotting   
Three  tumors  were  selected  randomly  from  control  or  EEHDW  group,  homogenized  in 
nondenaturing lysis buffer using homogeniser and centrifuged at 15,000×  g for 15 min followed by 
determination  of  protein  concentration  in  supernatants.  Equal  protein  per  lysate  was  resolved  on 
Tris-glycine gel, transferred onto PVDF membrane, and blocked for 2 h with 5% nonfat dry milk. 
Membranes were incubated with desired primary antibody Bcl-2, Bax, p21, Cyclin D1, CDK4, and 
β-actin  (at  a  dilution  of  1:1000)  overnight  at  4  ° C  and  then  with  appropriate  HRP-conjugated 
secondary antibody followed by enhanced chemiluminescence detection.   
2.11. Statistical Analysis 
Data  were  presented  as  mean  ±   SD  for  the  indicated  number  of  independently  performed 
experiments. The statistical analysis between groups was carried out using the Student’s t test and   
p < 0.05 was considered to be statistically significant.   
3. Results 
3.1. EEHDW Inhibits Tumor Growth in CRC Xenograft Mice 
The anti-tumor effect of EEHDW in vivo was evaluated by measuring tumor volume and weight in 
CRC xenograft mice, while its adverse effect was determined by measuring the body weight gain. As 
shown in Figures 2A,B, administration of EEHDW decreased tumor volume and weight by 52% and 
45%, respectively, compared with control. However, EEHDW treatment had no effect on the body 
weight  gain  in  experimental  animals  (Figure  2C).  These  data  suggest  that  EEHDW  can  inhibit 
colorectal tumor growth in vivo, without apparent signs of toxicity. 
Figure  2.  Effect  of  EEHDW  on  tumor  growth  in  CRC  xenograft  mice.  After  tumor 
development,  the mice were  given intra-gastric administration of  a  6 g/kg/day dose of 
EEHDW or saline daily, 5 days a week for 16 days. Tumor volume (A), tumor weight (B) 
and body weight (C) were measured at the end of the experiment. Data shown are averages 
with SD (error bars) from 12 individual mice in each group. * p  0.01, versus controls. 
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3.2. EEHDW Inhibits Cell Proliferation and Induces Apoptosis in CRC Xenograft Mice   
The  in  vivo  effect  of  EEHDW  on  cell  apoptosis  and  proliferation  was  determined  by 
immunohistochemical (IHC) staining for TUNEL and PCNA. Data in Figure 3 showed 22.0 ±  2.59% 
and  34.2  ±   3.19%  TUNEL-positive  cells  in  control  and  EEHDW-treated  mouse  groups,  and  the 
percentage  of  PCNA-positive  cells  in  control  and  EEHDW-treated  mice  was  37.8  ±   3.08%  and   
21.5 ±  4.22%, respectively. Taken together, it is demonstrated that EEHDW inhibits the proliferation of 
colorectal cancer cells and promotes cell apoptosis in vivo.   
Figure 3. Effect of EEHDW on cell apoptosis and proliferation in CRC mice. At the end   
of the experiment, tumor tissues were processed for immunohistochemical (IHC) staining 
for  TUNEL  (top)  or  PCNA  (bottom).  Left:  The  photographs  are  representative  images 
taken at a magnification of 400× . Right: Quantification of IHC assay is represented as 
percentage of positively-stained cells. Data shown are averages with SD (error bars) from 
10 individual mice in each group. * p  0.01, versus controls. 
 
3.3. EEHDW Inhibits the Phosphorylation of STAT3 in CRC Xenograft Mice   
The activation of STAT3 is mediated by phosphorylation at tyrosine residue 705. We therefore 
examined the effect of EEHDW on STAT3 phosphoralytion in tumor tissue by Western blot analysis 
using antibody that  recognizes  STAT3 phosphorylation at  Tyr
705.  As  shown in  Figure 4, EEHDW 
inhibited the phosphorylation of STAT3 in CRC mice, whereas the level of non-phosphorylated STAT3 
remained unchanged after EEHDW treatment, suggesting that EEHDW significantly suppresses the 
activation of STAT3 in vivo. 
3.4. EEHDW Regulates the Expression of Bcl-2, Bax, p21, Cyclin D1 and CDK4 in CRC   
Xenograft Mice   
To further explore the mechanism of EEHDW’s pro-apoptotic and anti-proliferative activities, we 
performed  RT-PCR  and  Western  Blot  analyses  to  examine  the  mRNA  and  protein  expression, Int. J. Mol. Sci. 2012, 13  6124 
 
respectively, of the pro-proliferative Cyclin D1, CDK4, anti-proliferative p21 and the pro-apoptotic 
Bax, anti-apoptotic Bcl-2. The results of the RT-PCR assay showed that EEHDW treatment profoundly 
reduced the mRNA expression of Bcl-2, p21, Cyclin D1, CDK4 but increased that of Bax and p21 in 
CRC  mice  (Figures  5A  and  C).  Data  from  Western  blot  analysis  showed  that  the  pattern  of  protein 
expression was similar to the respective mRNA levels (Figures 5 B,D). 
Figure  4.  Effect  of  EEHDW  on  phosphorylation  of  STAT3  in  CRC  xenograft  mice.   
(A)  Three  tumors  were  randomly  selected  from  each  group  and  the  level  of  STAT3 
phosphorylation in tumor tissues was determined by Western blot using an antibody that 
recognizes phosphorylated STAT3 at Tyr
705. β-actin was used as the internal control. For 
each  tumor  sample,  the  Western  blot  assay  was  performed  in  triple.  Data  shown  are 
representatives. (B) Densitometric analysis. The data were normalized to the mean protein 
expression of untreated control (100%). * p  0.01, versus controls. 
 
Figure 5. Effect of EEHDW on the expression of Bcl-2, Bax, p21, Cyclin D1 and CDK4 in 
CRC xenograft mice. (A,B) Three tumors were randomly selected from each group and the 
mRNA or protein expression levels of Bcl-2, Bax, p21, Cyclin D1, CDK4 were determined 
by RT-PCR (A) and Western blot analyses (B). GAPDH and β-actin were used as the 
internal controls for the RT-PCR or Western blotting, respectively. For each tumor sample, 
Western  blot  and  RT-PCR  analyses  were  was  performed  in  triple.  Data  shown  are 
representatives.  (C,D)  Densitometric  analysis.  The  data  were  normalized  to  the  mean 
mRNA (C) or protein (D) expression of untreated control (100%). * p < 0.01, versus controls.   
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4. Discussion 
To  date,  chemotherapy  is  one  of  the  main  therapeutic  approaches  for  patients  with  advanced 
colorectal  cancer  (CRC),  and  5-fluorouracil-based  regimens  are  the  standard  treatment  for  these 
patients. However, drug resistance and cytotoxicity against normal cells limit the long-term use, so it is 
necessary to develop multi-target agents with minimal side effects [24]. Natural products, including 
Traditional Chinese Medicine (TCM), have relatively fewer side effects and have been used clinically 
for thousands of years to treat various types of diseases, including cancer [5,25]. As a well-known and 
important Chinese medicinal herb, Hedyotis diffusa Willd (HDW) has been used as a major component 
in several TCM formulas for the clinical treatment of various types of cancer, including CRC, without 
apparent adverse effect [26–28]. However, the precise mechanism of its anti-cancer activity remains 
largely unclear.   
Cancer cells are characterized by an uncontrolled increase in cell proliferation and/or a reduction in 
cell  apoptosis  [29].  Bcl-2  family  proteins  are  key  regulators  of  apoptosis,  functioning  as  either 
suppressors such as Bcl-2, or promoters such as Bax. The ratio of active anti- and pro-apoptotic Bcl-2 
family members determines the fate of cells, and alteration of the ratio by aberrant expression of these 
proteins  impairs  the  normal  apoptotic  program  contributing  to  various  apoptosis-related  diseases 
including  cancer  [29,30].  Higher  Bcl-2  to  Bax  ratios  due  to  the  overexpression  of  Bcl-2  or 
down-regulation of Bax expression are commonly found in cancers, which not only confers a survival 
advantage to the cancer cells but also causes resistance to chemo- and radio-therapies. Eukaryotic cell 
proliferation is primarily regulated by cell cycle. G1/S transition is one of the two main checkpoints of 
the  cell  cycle  [31],  which  is  responsible  for  initiation  and  completion  of  DNA  replication.  G1/S 
progression is strongly regulated by Cyclin D1 that exerts its function via forming an active complex 
with its CDK major catalytic partners (CDK4/6) [32]. An unchecked or hyperactivated Cyclin D1/CDK4 
complex often leads to uncontrolled cell division and malignancy [33–36]. As a proliferation inhibitor, 
p21  protein  plays  a  role  in  G1  arrest  by  binding  to  and  inhibiting  the  activity  of  Cyclin-CDK 
complexes; and the decrease of p21 is associated with the promotion of tumor formation and a poor 
prognosis  in  many  types  of  cancer  [36,37].  The  transcription  factor  STAT3  is  essential  for  the 
regulation of cell apoptosis and proliferation. Phosphorylation of STAT3 at tyrosine 705 leads to its 
homodimerization, nuclear translocation and DNA binding, which in turn regulates the expression of Int. J. Mol. Sci. 2012, 13  6126 
 
various critical genes involved in cell proliferation and survival, such as the above-mentioned Bcl-2, 
Bax, p21, Cyclin D1 and CDK4 [10,11,38]. Constitutive activation of STAT3 facilitates an unregulated 
increase in cell proliferation and reduction in cell apoptosis resulting in the development of various 
cancers. Therefore, a re-balance of cell apoptosis and proliferation via regulating STAT3 pathway and 
its target gene expression has been a promising target for the development of anti-cancer therapies. 
Using a CRC mouse xenograft model, in the present study we reported that the ethanol extract of 
HDW (EEHDW) could inhibit cancer growth in vivo, without any noticeable toxicity. In addition, 
EEHDW  decreased  the  phosphorylation  activation  of  STAT3  in  CRC  mice.  Consequently,  the 
inhibitory effect of EEHDW on STAT3 activation resulted in the suppression of cell proliferation and 
the induction of cell apoptosis. Moreover, EEHDW treatment profoundly reduced the expression of 
anti-apoptotic Bcl-2, pro-proliferative Cyclin D1 and CDK4, as well as increased the expression of 
anti-proliferative p21 and pro-apoptotic Bax in vivo.   
5. Conclusions 
In  conclusion,  for  the  first  time  we  demonstrate  that  Hedyotis  diffusa  Willd  inhibits  colorectal 
cancer growth in vivo via promoting the apoptosis of cancer cells and inhibition of proliferation, which 
is mediated by the suppression of the STAT3 pathway. Our findings suggest that Hedyotis diffusa Willd 
may be a potential novel therapeutic agent for the treatment of cancers with constitutive activation   
of STAT3. 
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